Original Research

Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial

Hu XS, Han XH, Yang S, Li N, Wang L, Song YY, Mu H, Shi YK

Cancer Management and Research 2019, 11:4449-4459

Published Date: 13 May 2019